Trial Profile

Phase I Trial to Evaluate the Safety and Feasibility of CK0801 in Treatment of Bone Marrow Failure Syndrome

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CK 0801 (Primary)
Indications Aplastic anaemia; Bone marrow disorders; Myelodysplastic syndromes; Myelofibrosis
Focus Adverse reactions
Sponsors Cellenkos

Most Recent Events

13 Apr 2025 Planned End Date changed from 30 May 2024 to 30 May 2027.
13 Apr 2025 Planned primary completion date changed from 25 May 2024 to 25 May 2027.
05 Feb 2024 Planned End Date changed from 30 Jan 2024 to 30 May 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com